Merck appoints UK leadership team

pharmafile | January 26, 2010 | Appointment | |  MSD, Merck & Co, appointment 

Merck & Co’s UK business has unveiled its new leadership team, following last year’s merger with Schering-Plough.

Merck Sharp & Dohme’s Human Health Leadership Team appointments are:

Haseeb Ahmad – director of strategy

Keith Bousfield – director of primary care marketing

David Hewitt – director of consumer health

Jim Page – immunology business unit director

Kevin Peters – director of business operations

Chris Ponty – specialty business unit director

Kate Tillett – director of external affairs

Sally-Anne Tsangarides – hospital business unit director

Ilse van Roy – women’s health business unit director

Craig Wallace – primary care sales director

Tim Williams – director of market access

UK managing director Deepak Khanna said: “The outline shape for our organisation in the UK combines the strengths of both legacy companies.

Advertisement

“At the heart of our organisation is our aspiration to be viewed by the NHS as their most trusted and valued healthcare partner, and to make a substantial difference to patients.”

Related Content

David Wheadon appointed to board of directors at Seaport Therapeutics

This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Lung xray image

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070

Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …

Merck shares data from phase 3 trial of Keytruda for gastric cancers

Merck, known as MSD outside of the US and Canada, has announced data from the …

The Gateway to Local Adoption Series

Latest content